Trimethoprim 5 mg

Trimethoprim and sulfamethoxazole.

Trimethoprim or Tetroxoprim solution

Trimethoprim 66,7 mg Sulfadiazine 333,3 mg

Trimethoprim 58 mg/ g Sulfadiazine 288,3 mg/ g

Trimethoprim 5.78%w/ w Sulfadiazine 28.89 % w/ w

Trimethoprim or Tetroxoprim solution (see 5.1.3) (1) 10 ml

Trimethoprim 20 mg/ ml Sulfamethoxazole 100 mg/ ml N-Methyl-2-

Trimethoprim is a diaminopyrimidine, a synthetic folic acid antagonist.

Trimethoprim 2.6g and Sulfadiazine 13.0g tract, urogenital-tract and wound infections. should be continued for up to 5 days or until 2 days after symptoms have resolved.

Trimethoprim-sulfamethoxazole

Adverse reactions associated with the use of trimethoprim-sulfamethoxazole in patients without HIV infection are rare.

The antimicrobial combination of trimethoprim and sulfamethoxazole is active in vitro against varius gram-positive and gram-negative bacteria.

Whereas, in order to allow for the completion of scientific studies in progress, the duration of the validity of the provisional maximum residue limits previously defined in Annex III to Regulation (EEC) No 2377/90 should be extended for trimethoprim;

Sulfadiazine 333 mg Trimethoprim 67 mg

The Cmax of trimethoprim is 0.29 µg/ g.

Sulfadiazine 333 mg/ g Trimethoprim 67 mg/ g

Pro 100 g: Trimethoprim 6,66 g Sulfadiazine 33,34 g

333.3 mg/ g sulfadiazine and 66.7 mg/ g trimethoprim.

Sulfamethoxazole was co-administered with trimethoprim.

Each gram contains: Sulfadiazine 333 mg Trimethoprim 67 mg

1 g contains: Trimethoprim 58,00 mg, sulfadiazine 288,30 mg

Dissolve the components except trimethoprim or tetroxoprim in water.

Active substances per gram: Trimethoprim 66,7 mg Sulfadiazine 333,3 mg

25 mg sulfadiazine and 5 mg trimethoprim per kg BW per day, during max.

Sulphamethoxazole/ Trimethoprim 800 mg/ 160 mg BID (maraviroc 300 mg BID)

The pharmacokinetics of trimethoprim or sulfamethoxazole are not affected.

- inhibitors of dihydrofolate reductase (e. g. methotrexate, trimethoprim)

Add trimethoprim or tetroxoprim and sterilize at 121 p 1 oC for 15 minutes;

Administration of trimethoprim/ sulfamethoxazole 160 mg/ 800 mg results in a 40 % increase in lamivudine exposure, because of the trimethoprim component.

High trimethoprim concentrations are found in the kidneys, the liver and the lungs.

Trimethoprim/ sulfamethoxazole: no effect on the bioavailability of MPA was observed.

Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole.

Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole.

Infections in horses caused by micro-organisms sensitive to trimethoprim + sulphonamide

5-12 mg trimethoprim and 25-58 mg sulfamethoxasole per kg body weight per day for 3-5 days

Sulfamethoxazole/Trimethoprim2

5 mg trimethoprim and 25 mg sulfadiazine per kg body weight per day to a maximum of 5 days.

Pigs:20.8 mg sulfamethoxasole + 4.2 mg trimethoprim per kg body weight per day for 3-4 days.

Indinavir and sulphamethoxazole/ trimethoprim can be co- administered without dose adjustment.

Antibiotics Sulphamethoxazole/ Trimethoprim 800 mg/ 160 mg BID (Indinavir 400 mg QID) Antifungals

Preparation Dissolve the trimethoprim or tetroxoprim in ethanol (5 or 30 ml) and dilute with water.

Administration of trimethoprim/ sulfamethoxazole 160 mg/ 800 mg results in a 40 % increase in lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component does not interact.

Administration of trimethoprim/ sulphamethoxazole 160 mg/ 800 mg increased lamivudine exposure by about 40 %.

Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided.

Dose alteration of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should not be necessary.

For treatment of infections caused by organisms sensitive to combination of trimethoprim and sulfamethoxasole.

Whereas danofloxacin, cefazolin and trimethoprim should be inserted into Annex I to Regulation (EEC) No 2377/90;